tetano
Editor, Senior Moderator
Front Immunol
. 2024 Nov 18:15:1420284.
doi: 10.3389/fimmu.2024.1420284. eCollection 2024. Quantification of heterogeneity in human CD8[SUP]+[/SUP] T cell responses to vaccine antigens: an HLA-guided perspective
Duane C Harris[SUP] 1 [/SUP], Apoorv Shanker[SUP] 2 [/SUP], Makaela M Montoya[SUP] 2 [/SUP], Trent R Llewellyn[SUP] 2 [/SUP], Anna R Matuszak[SUP] 2 [/SUP], Aditi Lohar[SUP] 2 [/SUP], Jessica Z Kubicek-Sutherland[SUP] 2 [/SUP], Ying Wai Li[SUP] 3 [/SUP], Kristen Wilding[SUP] 1 [/SUP], Ben Mcmahon[SUP] 1 [/SUP], Sandrasegaram Gnanakaran[SUP] 1 [/SUP], Ruy M Ribeiro[SUP] 1 [/SUP], Alan S Perelson[SUP] 1 [/SUP], Carmen Molina-París[SUP] 1 [/SUP]
Affiliations
Vaccines have historically played a pivotal role in controlling epidemics. Effective vaccines for viruses causing significant human disease, e.g., Ebola, Lassa fever, or Crimean Congo hemorrhagic fever virus, would be invaluable to public health strategies and counter-measure development missions. Here, we propose coverage metrics to quantify vaccine-induced CD8[SUP]+[/SUP] T cell-mediated immune protection, as well as metrics to characterize immuno-dominant epitopes, in light of human genetic heterogeneity and viral evolution. Proof-of-principle of our approach and methods are demonstrated for Ebola virus, SARS-CoV-2, and Burkholderia pseudomallei (vaccine) proteins.
Keywords: CD8 + T cell; HLA class I; correlate of protection; coverage metric; epitope; immune response; immuno-dominant; vaccine.
. 2024 Nov 18:15:1420284.
doi: 10.3389/fimmu.2024.1420284. eCollection 2024. Quantification of heterogeneity in human CD8[SUP]+[/SUP] T cell responses to vaccine antigens: an HLA-guided perspective
Duane C Harris[SUP] 1 [/SUP], Apoorv Shanker[SUP] 2 [/SUP], Makaela M Montoya[SUP] 2 [/SUP], Trent R Llewellyn[SUP] 2 [/SUP], Anna R Matuszak[SUP] 2 [/SUP], Aditi Lohar[SUP] 2 [/SUP], Jessica Z Kubicek-Sutherland[SUP] 2 [/SUP], Ying Wai Li[SUP] 3 [/SUP], Kristen Wilding[SUP] 1 [/SUP], Ben Mcmahon[SUP] 1 [/SUP], Sandrasegaram Gnanakaran[SUP] 1 [/SUP], Ruy M Ribeiro[SUP] 1 [/SUP], Alan S Perelson[SUP] 1 [/SUP], Carmen Molina-París[SUP] 1 [/SUP]
Affiliations
- PMID: 39624092
- PMCID: PMC11608996
- DOI: 10.3389/fimmu.2024.1420284
Vaccines have historically played a pivotal role in controlling epidemics. Effective vaccines for viruses causing significant human disease, e.g., Ebola, Lassa fever, or Crimean Congo hemorrhagic fever virus, would be invaluable to public health strategies and counter-measure development missions. Here, we propose coverage metrics to quantify vaccine-induced CD8[SUP]+[/SUP] T cell-mediated immune protection, as well as metrics to characterize immuno-dominant epitopes, in light of human genetic heterogeneity and viral evolution. Proof-of-principle of our approach and methods are demonstrated for Ebola virus, SARS-CoV-2, and Burkholderia pseudomallei (vaccine) proteins.
Keywords: CD8 + T cell; HLA class I; correlate of protection; coverage metric; epitope; immune response; immuno-dominant; vaccine.